#5 – Nerding Out at ECCMID 2019

07/10/19 • 29 min

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) share their secret passions and nerdiest moments from ECCMID 2019, including multi-omics data for Pseudomonas aeruginosa, the effects of chemotherapy on antimicrobial resistance, phage therapy, and more!

Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Previous Episode

#4 – How ECCMID 2019 went viral

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review results of ASPECT-NP (Ceftolozane-tazobactam versus meropenem in patients with ventilated nosocomial pneumonia), CAMERA-2 (Combination therapy for methicillin-resistant Staphylococcus aureus bacteraemia), and Exebacase for patients with methicillin-resistant Staphylococcus aureus bacteraemia (Phase 2).

Next Episode

#6 – Tazobactam and Tulips: Hot Topics from ECCMID 2019

Erin McCreary (@erinmccreary) and Ryan Shields (@ryankshields) review expanded MERINO trial data including mortality by pathogen MIC, PK-PD principles, BLING III, beta-lactam therapeutic drug monitoring, linezolid dosing in renal impairment, microbiology issues, and updates from EUCAST.

CORRECTION: Piperacillin-tazobactam was dosed 4.5g IV every 6 hours in the Merino trial.